HIV/AIDS
Findings in HIV/AIDS reported from Temple University
Published in AIDS Weekly, April 28th, 2008
"Differences in adverse events by gender and race/ethnicity have not been described extensively in randomized clinical trials of HIV antiretroviral therapy (ART). Antiretroviral-naive HIV-infected participants enrolled in a long-term randomized clinical trial of 3 different initial ART strategies-protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or PI plus NNRTI-based combinations with a median follow-up of 5 years, were compared by gender and race for 14 categories of grade 4 adverse events, discontinuation of initial antiretroviral regimen, and all-cause mortality," researchers in the United States report.
"Multivariate analysis was used...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-04-28)
More Articles from AIDS Weekly
- HIV/AIDS
Cutting through the stigma - Drug Resistance
Reports from University of Liverpool highlight recent research in drug resistance - Hemochromatosis
Researchers at Vanderbilt University target hemochromatosis - HIV/AIDS
Brown University publishes research in HIV/AIDS - HIV/AIDS
Internet Sexuality Information Services (ISIS) Exposes Ideas for Preventing HIV and other STDs with an Underwear Design Contest - HIV/AIDS
Investigators at University of Toronto publish new data on HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
